COMP <GO>
ADPT vs LLY // EV/EBITDA & P/E VALUATION
Adaptive Biotechnologies Corporation (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: ADPT 3
— LLY 11
■ METRIC PARITY
LAST: $26.64 (-5.43%) • MKT CAP: $4.50B
valuation
—
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
valuation
36.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ADPT VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ADPT | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.20% | 83.64% | -9.44 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -12.50% | 32.36% | -44.86 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.09% | 2.30% | -3.39 | LLY | /fcf-yield <GO> |
| Operating Margin | -20.60% | 40.21% | -60.81 | LLY | /operating-margins <GO> |
| Net Profit Margin | -21.50% | 31.90% | -53.40 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 54.80% | 45.51% | +9.29 | ADPT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.32 | 9.29 | -2.97 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 9/9 | -3.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.77% | +0.13 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.3 | 77.9 | -26.63 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.01 | 0.51 | +0.50 | ADPT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.0x | 26.3x | -0.25 | ADPT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.50B | $1.33T | -$1.33T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ADPT REV | LLY REV | ADPT GROSS % | LLY GROSS % | ADPT FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $277.0M | $65.18B | 74.2% | 83.0% | -$48.9M | $16.81B |
| FY 2024 | $179.0M | $45.04B | 59.7% | 81.3% | -$98.9M | $8.82B |
| FY 2023 | $170.3M | $34.12B | 44.0% | 79.3% | -$164.0M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ADPT // BETA 1.01
LLY // BETA 0.51